Pomalidomide-C6-PEG3-butyl azide

Background Introduction

Pomalidomide-C6-PEG3-butyl azide is a specialized E3 ligase ligand-linker conjugate, designed for use in Proteolysis Targeting Chimera (PROTAC) and targeted protein degradation research. It incorporates the immunomodulatory drug (IMiD) pomalidomide, which binds to the CRBN E3 ubiquitin ligase, with a C6-PEG3 linker ending in a reactive butyl azide group. This modular structure facilitates the development of bifunctional molecules through click chemistry, enabling the precise targeting and degradation of specific proteins.

Mechanism

The mechanism of Pomalidomide-C6-PEG3-butyl azide is based on the PROTAC strategy. The pomalidomide moiety acts as a ligand for the CRBN E3 ubiquitin ligase, recruiting it to the target protein of interest. The C6-PEG3 flexible linker provides optimal spatial orientation and solubility, while the terminal butyl azide enables bioorthogonal conjugation with alkyne-tagged targeting ligands via copper-catalyzed azide-alkyne cycloaddition (CuAAC). Once a bifunctional PROTAC is synthesized using this conjugate, it brings the E3 ligase and target protein into proximity, leading to ubiquitination and subsequent proteasomal degradation of the target protein within the cell.

Applications

Pomalidomide-C6-PEG3-butyl azide is widely used in drug discovery and chemical biology for the synthesis of CRBN-based PROTACs aimed at selective protein degradation. It enables rapid assembly of customized PROTAC libraries via click chemistry, accelerating the exploration of targeted protein knockdown in cancer, neurodegenerative diseases, and other therapeutic areas. The product is ideal for researchers developing next-generation degraders, validating novel drug targets, or investigating the biology of E3 ligase-mediated ubiquitination pathways.

• Azide-functionalized PEG3 linker enables versatile Click Chemistry conjugation for custom PROTAC design.
• Pomalidomide moiety ensures high affinity and selectivity for CRBN E3 ligase recruitment in targeted protein degradation.

Pomalidomide-C6-PEG3-butyl azide is an E3 Ligase Ligand-Linker Conjugate designed for use in PROTACs, facilitating targeted protein degradation. Its structure allows for effective ubiquitination of target proteins, offering advantages in selectivity and degradation efficiency. The following provides a detailed description of this molecule's linker, ligand, and selection of target protein ligands.

Linker: The linker in this molecule is a C6-PEG3 chain, providing a balance of flexibility and rigidity. It is non-cleavable, ensuring stability in biological systems, and its length supports optimal spatial orientation between the ligand and the target protein.

Ligand: The ligand is based on pomalidomide, an immunomodulatory drug known for its ability to recruit the cereblon E3 ubiquitin ligase. Its structural characteristics ensure high binding affinity and specificity, enhancing the efficacy of the PROTAC.

Reactive Site: The reactive site of this molecule is the butyl azide group, which couples with the target protein ligand via click chemistry reactions such as azide-alkyne cycloaddition. This site ensures efficient conjugation, facilitating the formation of a stable PROTAC complex.

Recommended Target Protein Ligand: The recommended target protein ligand is an alkyne-functionalized warhead, which pairs effectively with the butyl azide group. This warhead allows for precise targeting and degradation of the protein of interest, making it suitable for applications in probing protein function and validating therapeutic targets in experimental studies.